In 2016, Strickland et al. reported that high grade serous ovarian cancers with BRCA1/2 mutations and a high number of tumor-infiltrating lymphocytes (TILs) were associated with elevated expression of PD-1/PD-L140. The gene discussed is BRCA1; the disease is ovarian serous adenocarcinoma.